Agenus (AGEN) News Today → BUY ALERT: Tiny tech play partners with US government (From Stansberry Research) (Ad) Free AGEN Stock Alerts $15.03 -0.22 (-1.44%) (As of 05/29/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 10:32 AM | seekingalpha.comAgenus: Multiple Milestones In The Second Half Of 2024May 27 at 12:32 PM | investorplace.com7 Biotech Stocks to Put on Your Breakthrough RadarMay 26, 2024 | americanbankingnews.comAgenus (NASDAQ:AGEN) Stock Rating Reaffirmed by HC WainwrightMay 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Agenus Amid Promising Colorectal Cancer Study ResultsMay 24, 2024 | businesswire.comAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 24, 2024 | marketbeat.comAgenus (NASDAQ:AGEN) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Agenus in a report on Friday.May 23, 2024 | businesswire.comBreakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual MeetingMay 23, 2024 | businesswire.comAgenus to Participate in Goldman Sachs 45th Annual Global Healthcare ConferenceMay 22, 2024 | fool.com3 Magnificent Growth Stocks to Buy Hand Over FistMay 18, 2024 | uk.investing.comAgenus sets FDA meeting for cancer therapy pathMay 16, 2024 | finance.yahoo.comFDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal CancerMay 16, 2024 | businesswire.comFDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal CancerMay 15, 2024 | insidermonkey.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2024 Earnings Call TranscriptMay 13, 2024 | marketbeat.comShort Interest in Agenus Inc. (NASDAQ:AGEN) Rises By 25.1%Agenus Inc. (NASDAQ:AGEN - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 3,240,000 shares, an increase of 25.1% from the April 15th total of 2,590,000 shares. Based on an average daily trading volume, of 795,200 shares, the days-to-cover ratio is currently 4.1 days. Currently, 16.8% of the company's stock are sold short.May 10, 2024 | markets.businessinsider.comBuy Rating for Agenus Inc. on Strong Financial Position and Promising Clinical MilestonesMay 10, 2024 | marketbeat.comAgenus Inc. Forecasted to Earn Q2 2024 Earnings of ($3.10) Per Share (NASDAQ:AGEN)Agenus Inc. (NASDAQ:AGEN - Free Report) - Equities researchers at HC Wainwright raised their Q2 2024 earnings per share estimates for Agenus in a report issued on Tuesday, May 7th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings of ($3.10) per shaMay 9, 2024 | seekingalpha.comAgenus GAAP EPS of -$3.04 beats by $0.18, revenue of $28M misses by $19.17MMay 8, 2024 | finance.yahoo.comAgenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comAgenus First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 8, 2024 | finance.yahoo.comAgenus Inc (AGEN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...May 7, 2024 | washingtonpost.comAgenus: Q1 Earnings SnapshotMay 7, 2024 | msn.comAGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | fool.comAgenus (AGEN) Q1 2024 Earnings Call TranscriptMay 7, 2024 | marketbeat.comAgenus (NASDAQ:AGEN) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Agenus in a research note on Tuesday.May 7, 2024 | finance.yahoo.comAgenus Inc (AGEN) Q1 2024 Earnings: Misses Revenue and EPS Estimates Amid Strategic DevelopmentsMay 7, 2024 | businesswire.comAgenus Reports First Quarter 2024 ResultsMay 7, 2024 | businesswire.comLigand and Agenus Enter Into $100 Million Royalty Financing AgreementMay 1, 2024 | msn.comWhat to Make of Agenus Stock (NASDAQ:AGEN) Post Reverse Stock SplitMay 1, 2024 | finance.yahoo.comAgenus Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 30, 2024 | seekingalpha.comTime Is Running Out For Agenus To Raise CashApril 30, 2024 | marketbeat.comAgenus (AGEN) Scheduled to Post Earnings on TuesdayAgenus (NASDAQ:AGEN) will be releasing earnings before the market opens on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=587670)April 29, 2024 | msn.comCompare with S&P 500 Growth Index SGD Total Return (500GST)April 28, 2024 | fool.comUp 40%: Is This Red-Hot Growth Stock Still a Buy?April 28, 2024 | fool.comUp 40%: Is This Red-Hot Growth Stock Still a Buy?April 27, 2024 | finance.yahoo.comAgenus Inc. (AGEN)April 25, 2024 | marketbeat.comAgenus Inc. (NASDAQ:AGEN) Short Interest UpdateAgenus Inc. (NASDAQ:AGEN - Get Free Report) saw a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 2,590,000 shares, a drop of 94.6% from the March 31st total of 47,720,000 shares. Approximately 13.0% of the company's stock are short sold. Based on an average daily trading volume, of 665,300 shares, the days-to-cover ratio is presently 3.9 days.April 24, 2024 | finance.yahoo.comBotensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual MeetingApril 23, 2024 | benzinga.comTop 2 Health Care Stocks Which Could Rescue Your Portfolio This Month - Agenus (NASDAQ:AGEN), MultiPlan (NYSE:MPLN)April 23, 2024 | businesswire.comAgenus to Provide First Quarter 2024 Financial Report and Corporate UpdateApril 13, 2024 | nasdaq.comCommit To Purchase Agenus At $1, Earn 2607.1% Annualized Using OptionsApril 12, 2024 | markets.businessinsider.comSmall-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns LoomApril 12, 2024 | nasdaq.comAgenus Updates Phase 1 Data Of BOT/BAL Therapy In MSS Metastatic Colorectal CancerApril 12, 2024 | markets.businessinsider.comAgenus Stock Falls After Reporting Updated Phase 1 Data On Colorectal Cancer TherapyApril 12, 2024 | msn.comAgenus reports updated Phase 1 data on colorectal cancer therapyApril 12, 2024 | marketbeat.comAgenus (NASDAQ:AGEN) Reaches New 12-Month Low at $8.10Agenus (NASDAQ:AGEN) Reaches New 52-Week Low at $8.10April 12, 2024 | finance.yahoo.comAgenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal CancerApril 12, 2024 | businesswire.comAgenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal CancerApril 12, 2024 | marketbeat.comTrading was temporarily halted for "AGEN" at 07:04 PM with a stated reason of "News pending."April 8, 2024 | marketbeat.comAgenus (NASDAQ:AGEN) Shares Scheduled to Reverse Split on Friday, April 12thAgenus Inc. (NASDAQ:AGEN - Free Report)'s stock is set to reverse split before the market opens on Friday, April 12th. The 1-20 reverse split was announced on Friday, April 12th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, April 12th.April 8, 2024 | marketwatch.comMiNK Therapeutics' MiNK-215 Data Show Potential Treatment for Liver Metastases Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Are You Positioned For The New Energy Goldrush? (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy. Click here to get all the information about it. AGEN Media Mentions By Week AGEN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGEN News Sentiment▼0.460.80▲Average Medical News Sentiment AGEN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGEN Articles This Week▼103▲AGEN Articles Average Week Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Poseida Therapeutics News Adaptimmune Therapeutics News Sutro Biopharma News Athira Pharma News Precision BioSciences News Aligos Therapeutics News Innoviva News OPKO Health News Ironwood Pharmaceuticals News Lexicon Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGEN) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTradeThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchGold Set to EXPLODE!Gold Safe Exchange[Urgent!] Generational Wealth GameplanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.